Toxicities of novel therapies for hematologic malignancies

References

• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. [Internet]. 2017 [cited 2019 Jun 16];390:2790–2802. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673617321347
   PubMed Web of Science ®Google Scholar
• Kreissl S, Mueller H, Goergen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. Available from. 2016 [cited 2019 Oct 31];17:1453–1462. [Internet] http://www.ncbi.nlm.nih.gov/pubmed/27612583
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. [Internet]. 2019 [cited 2019 May 15];1. Available from: http://www.nature.com/articles/s41571-019-0218-0
   Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. [Internet]. Lancet Oncol. 2016;17:1283–1294.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 1;35(19):2125–2132.
   Google Scholar
• Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma. J Clin Oncol. 2019;37:3291–3299. JCO.19.01389.
   Google Scholar
• Petrelli F, Ardito R, Borgonovo K, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. [Internet]. 2018 [cited 2019 May 18];103:7–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30196108
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. [Internet]. 2017 [cited 2019 Jun 13];389:255–265. Available from: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)32517-X.pdf
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–1728.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119–iv142.
   PubMed Web of Science ®Google Scholar
• Weber JS, Seigel C, Phillips T, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–1768.
   PubMedGoogle Scholar
• Quach HT, Dewan AK, Davis EJ, et al. Association of anti–programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. [Internet]. 2019 [cited 2019 May 9];5:906. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0046
   PubMed Web of Science ®Google Scholar
• Maher VE, Fernandes LL, Weinstock C, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol [Internet]. 2019 [cited 2019 May 29];JCO1900318. Available from: https://ascopubs.org/doi/10.1200/JCO.19.00318.
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci. 2010;107:13075–13080.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432–443.
   PubMed Web of Science ®Google Scholar
• Dimou M, Iliakis T, Pardalis V, et al. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece. Leuk Lymphoma. 2019;60:2939–2945.
   Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425–2437.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133:2031–2042.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
   PubMed Web of Science ®Google Scholar
• Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. Blackwell Publishing Ltd; 2017;15:835–847.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: european recommendations for clinical practice. Br J Haematol. 2018;180:666–679.
   PubMed Web of Science ®Google Scholar
• Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128:138–140.
   PubMed Web of Science ®Google Scholar
• Dickerson T, Wiczer T, Waller A, et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134:1919–1928. blood.2019000840.
   PubMed Web of Science ®Google Scholar
• Ahn IE. Cardiovascular adverse events of ibrutinib. Blood J Am Soc Hematol. 2019;1881–1882.
   Google Scholar
• Rogers KA, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. Nature Publishing Group; 2019;33:2527–2530.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659–667.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial. Blood. 2018;132:148.
   PubMed Web of Science ®Google Scholar
• Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018;132:2249–2259.
   PubMed Web of Science ®Google Scholar
• Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, et al. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159–170.e2.
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal Antibodies: A Review. Curr Clin Pharmacol. 2018;13:85–99.
   PubMed Web of Science ®Google Scholar
• Picard M, Galvão VR. Current knowledge and management of hypersensitivity reactions to monoclonal antibodies. J Allergy Clin Immunol Pract. 2017;5:600–609.
   PubMed Web of Science ®Google Scholar
• Rituxan (rituximab) FDA Approval History - Drugs.com.
   Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–1110.
   PubMed Web of Science ®Google Scholar
• Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377:1331–1344.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137–146.
   PubMed Web of Science ®Google Scholar
• Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24:323–331.
   PubMed Web of Science ®Google Scholar
• Law MF, Ho R, Cheung CKM, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016 Jul 28;22(28):6484–6500.
   Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–1560.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. [Internet]. 2015 [cited 2019 Dec 12];373:621–631. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1505654
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. [Internet]. 2019 [cited 2019 Nov 10]:JCO1900172. Available from: http://ascopubs.org/doi/10.1200/JCO.19.00172
   Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–1531.
   PubMed Web of Science ®Google Scholar
• Han X, Yu S, Li A, et al. Recent advances of bispecific antibodies in solid tumors. J Hematol Oncol. BioMed Central Ltd. 2017 Sep 20;10(1):155.
   Web of Science ®Google Scholar
• Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood J Am Soc Hematol. 2018;30–38.
   Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. [Internet]. 2019 [cited 2019 Sep 11];25:1341–1355. Available from: http://www.nature.com/articles/s41591-019-0564-6
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 3;380(1):45–56.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:7505.
   Web of Science ®Google Scholar
• Garcia Borrega J, Gödel P, Rüger M, et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere. 2019;3(2):e191.
   Web of Science ®Google Scholar
• Feinberg D, Paul B, Kang Y. The promise of Chimeric Antigen Receptor (CAR) T cell therapy in multiple myeloma. Cell Immunol. 2019;345:103964.
   PubMed Web of Science ®Google Scholar
• Gödel P, Shimabukuro-Vornhagen A, von Bergwelt-baildon M. Understanding cytokine release syndrome. Intensive Care Med. 2018;44:371–373.
   PubMed Web of Science ®Google Scholar
• Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37:48–52.
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739–748.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66:50–52.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar
• Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–1419.
   PubMed Web of Science ®Google Scholar
• Rice J, Nagel S, Randall J, et al. Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment. Curr Treat Options Neurol. 2019;21:40.
   PubMed Web of Science ®Google Scholar
• Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958–971.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hay KA, Li D, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Speci fi c chimeric antigen receptor – modi fi ed T cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010–3020.
   PubMed Web of Science ®Google Scholar
• Taraseviciute A, Tkachev V, Ponce R, et al. Chimeric antigen receptor T cell–mediated neurotoxicity in nonhuman primates. Cancer Discov. 2018;8:750–763.
   PubMed Web of Science ®Google Scholar
• Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy : cytokine release syndrome, neurologic toxicity, and financial burden. Sante publique (Vandoeuvre-les-Nancy, France). 2019;Vol. 31:433–444.
   PubMedGoogle Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625–638.
   Web of Science ®Google Scholar
• Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11:eaau5907.
   PubMed Web of Science ®Google Scholar
• Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood. 2017;130:2295–2306.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi L, Berger C, et al. CD19 CAR – T cells of defined CD4 + : CD8 + composition in adult B cell ALL patients. J Clin Invest. 2016;1:1–16.
   Google Scholar
• Mirzaei HR, Till BG. Predictive and therapeutic biomarkers in chimeric antigen receptor T ‐ cell therapy : A clinical perspective. J Cell Physiol. 2019 May;234(5):5827–5841.
   Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47–62.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. Churchill Livingstone; 2019;34:45–55.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell‐induced severe or life‐threatening cytokine release syndrome. Oncologist. 2018;23:943–947. theoncologist.2018-0028.
   PubMed Web of Science ®Google Scholar
• Taraseviciute A, Gust J, Leger K. Preemptive mitigation of CD19 CAR T Cell cytokine release syndrome without attenuation of anti-leukemic efficacy preemptive mitigation of CD19 CAR T cell cytokine release syndrome without attenuation of anti-leukemic efficacy. Blood. 2019 Dec 12;134(24):2149–2158.
   Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130:1547LP– 1547.
   Web of Science ®Google Scholar
• Garcia Borrega J, Gödel P, Rüger MA, et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. HemaSphere. 2019;3:1–11.
   Web of Science ®Google Scholar
• Jacobson CA, Hunter B, Armand P, et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood. 2018;132:92.
   Web of Science ®Google Scholar
• Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371:906–917.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127:3215–3224.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25:4264–4270.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
   PubMed Web of Science ®Google Scholar
• Ben WJ, Stamatoullas A, Huebner D, et al. Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. Br J Haematol. 2019 Jan;184(2):202–214.
   Web of Science ®Google Scholar
• Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. Elsevier Ltd; 2018;5:e563–e598.
   PubMed Web of Science ®Google Scholar
• Scott JM, Dolan LB, Norton L, et al. Multisystem Toxicity in Cancer: lessons from NASA’s Countermeasures Program. Cell. Cell Press; 2019;179:1003–1009.
   PubMed Web of Science ®Google Scholar